摘要
目的 研制产朊假丝酵母尿酸酶纳米脂质体（nanoliposomes containing uricase from candida utilis， UCCNLs）并对其理化性质和体外活性进行评价。 方法 采用逆向蒸发法制备UCCNLs，以包封率、最小多分散指数、粒径等为评价指标优化制备工艺。考察体外降尿酸活性。考察4，25 ℃纳米粒的稳定性。结果 醚水比为3∶1，脂醇比为1∶1，投药量为2 mg时，UCCNLs的平均包封率为64.24%，平均粒径为206.73 nm，多分散系数为0.247，Zeta电位为-37.33 mV。将尿酸从0.595 mol·L-1降至正常水平UCCNLs所需时间约为游离酶的一半。UCCNLs在4 ℃时具有良好的稳定性。结论 采用逆向蒸发法可制备UCCNLs，工艺简便，包封率高，稳定性较好，体外降尿酸效果好。
Abstract
OBJECTIVE To prepare lipid nanoparticles containing uricase from candida utilis（UCCLNs）and to investigate their properties. METHODS UCCLNs were prepared by reverse-phase evaporation method. The entrapment efficiency， polydispersity index， size， and et al. were set as evaluation indexes for optimizing preparation METHODS. Uricolytic activity in vitro and the stability of drug loaded lipid nanoparticles were investigated. RESULTS The best formula for UCCLNS was as follows： the volume ratio of diethyl ether and buffer was 3∶1； the molar ratio of phosphatidylcholine and cholesterol 1∶1； and the uricase amount 2 mg. The entrapment efficiency was 64.24%， average particle size was 206.73 nm， and Zeta potential was -37.33 mV. Compared with native uricase solution， it took about a half time for decreasing uric acid from 0.595 mmol·L-1 to normal level when the same dosage of UCCLNs were given. UCCLNs were stable under storage conditions. CONCLUSION UCCLNs can be prepared by reverse-phase evaporation method， with the advantages of simple process， small diameter and polydispersity， high encapsulation ratio， good stability and high uricolytic activity.
关键词
产朊假丝酵母尿酸酶 /
纳米脂质体 /
制备 /
理化性质
{{custom_keyword}} /
Key words
Uricase from candida utilis /
lipid nanoparticles /
preparation /
physical-chemical property
{{custom_keyword}} /
刘娟 谭群友 王娜 熊华蓉 赵春景 张景勍.
产朊假丝酵母尿酸酶纳米脂质体的研制及其理化性质[J]. 中国药学杂志, 2011, 46(15): 1184-1188
LIU Jun;TN Qun-you;WNG N;XIONG Hu-rong;ZHO Chun-jing;ZHNG Jing-qing.
Preparation and Characterization of Uricase Loaded in Lipid Nanoparticles[J]. Chinese Pharmaceutical Journal, 2011, 46(15): 1184-1188
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ HUMMEL M， BUCHHEIDT D， REITER S， et al. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematolagic malignancy and tumor lysis syndrome ［J］. Leukemia， 2003， 17（12）： 2542-2544.
［2］ SHERMAN M R， SAIFER M G P， PEREZRUIZ F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia ［J］. Adv Drug Deliv Rev， 2008， 60（1）： 59-68.
［3］ CHEN Y，DENGY J，HAOY L，et al. Preparation of cardiomyo-cyte-targeting liposomes and their targeting ability in vitro［J］. Acta Pharm Sin （药学学报）， 2005， 40（6）： 568-572.
［4］ BRADFORD M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding ［J］. Anal Biochem， 1976， 72（1-2）： 248-254.
［5］ GEORGIOU C D， GRINTZALIS K， ZERVOUDAKIS G， et al. Mechanism of Coomassie brilliant blue G-250 binding to proteins： a hydrophobic assay for nanogram quantities of proteins ［J］. Anal Bioanal Chem， 2008， 391（1）： 391-403.
［6］ MERTINS O， SEBBEN M， POHLMANN A R， et al. Production of soybean phosphatidylcholine-chitosan nanovesicles by reverse phase evaporation： a step by step study ［J］. Chem Phys Lipids， 2005， 138（1-2）： 29-37.
［7］ LU B， ZHANG J， YANG H. Nonphospholipid vesicles of carboplatin for lung targeting ［J］. Drug Deliv， 2003， 10（2）： 87-94.
［8］ STOVE V， WUYTS B， DELANGHE J. Perchloric acid treatment to stabilize uric acid concentrations in blood samples of patients receiving uric acid oxidase （rasburicase） therapy ［J］. Clin Chem， 2007， 15（2）： 369-370.
［9］ ZHAO Y S， ZHAO L， YANG G Q， et al. Characterization of uricase from bacillus fastidious A. T. C. C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method ［J］. Biotechnol Appl Biochem， 2006， 45（2）： 75-80.
［10］ YOSHIMOTO M， WANG S， FUKUNAGA K， et al. Enhancement of apparent substrate selectivity of proteinase K encapsulated in liposomes through a cholate-induced alteration of the bilayer permeability［J］. Biotechnol Bioeng， 2004， 85（2）： 222-233.
［11］ KUBOI R， YOSHIMOTO M， WALDE P， et al. Refolding of carbonic anhydrase assisted by 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine liposomes ［J］. Biotechnol Prog， 1997， 13（6）： 828-836.
［12］ YOSHIMOTO M， WANG S， FUKUNAGA K， et al. Novel immobilized liposomal glucose oxidase system using the channel protein ompf and catalase ［J］. Biotechnol Bioeng， 2005， 90（2）： 231-238.
［13］ NISHIDA Y， KAMATANI N， MIYAMOTO T. Hypouricaemic effect after oral administration in chichens of poly-ethylene glycol-modified uricase entrapped in liposomes ［J］. Pharm Pharmacol， 1984， 36（5）： 354-355.
［14］ YOSHIMOTO M， MIYAZAKI Y， KUDO Y， et al. Glucose oxidation catalyzed by liposomal glucose oxidase in the presence of catalasecontaining liposomes ［J］. Biotechnol Prog， 2006， 22（3）： 704-709.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1531 KB)
